Anna Minchom

Platelet factor 4–induced T _H 1-T _reg polarization suppresses antitumor immunity

Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies

Macrophages in immunoregulation and therapeutics

Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis

To control or to be controlled? Dual roles of CDK2 in DNA damage and DNA damage response

Regulation and Function of the PD-L1 Checkpoint

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth

Clinical relevance of tumour-associated macrophages

Macrophages as tools and targets in cancer therapy

Tumor microenvironment and cancer therapy resistance

Breast Cancer Statistics, 2022

Binder jet 3D printing—Process parameters, materials, properties, modeling, and challenges

Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment

Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment

Symptom Burden, Survival and Palliative Care in Advanced Soft Tissue Sarcoma

Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies

Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma

Abstract PD3-07: Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study

BRIM-1, -2 and -3 Trials: Improved Survival with Vemurafenib in Metastatic Melanoma Patients with a BRAF ^V600E Mutation